[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"reproductive-issues\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:reproductive-issues":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,70,90,106,140,165,187,206,231],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100628035","development-of-an-ai-platform-for-the-analysis-of-sperm-and-prediction-of-their-clinical-potential-100628035",false,"NCT07456397","Development of an AI Platform for the Analysis of Sperm and Prediction of Their Clinical Potential","Development and Validation of an Artificial Intelligence Platform for the Analysis of Sperm Samples and Prediction of Their Clinical Potential","Spermy01","Male participants:\n\nInclusion Criteria:\n\n* Ability to provide a semen sample via masturbation\n* Semen sample intended for use in an IVF\u002FICSI cycle\n\nExclusion Criteria:\n\n* Current diagnosis of a sexually transmitted infection (STI)\n* Previous diagnosis of hepatitis A, B, C, D, or HIV\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months\n\nFemale participants:\n\nInclusion Criteria:\n\n* Urdengoing an IVF\u002FICSI cycle with partner or donor semen\n\nExclusion Criteria:\n\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months","ALL","18 Years","60 Years",{"count":21,"type":22},500,"ESTIMATED","OBSERVATIONAL","Prospective, multicenter research study with a split-sample design on semen samples, without intervention, to develop an artificial intelligence platform for the analysis of sperm samples and prediction of their clinical potential, in 500 semen samples, in an in vitro study over 24 months.",[26,27,28,29,30],"Infertility (IVF Patients)","ICSI","IVF Outcomes","Male Infertility","Reproductive Issues","RECRUITING","2026-06-10",{"date":34,"type":35},"2026-06-12","ACTUAL",{"date":37,"type":35},"2026-03-18",{"date":39,"type":22},"2028-02",{"name":41,"class":42},"Fecundis Lab SL","OTHER",5,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100638418","the-efficacy-and-safety-of-female-prp-co-incubation-with-sperm-during-iui-cycles-100638418","NCT07615634","The Efficacy and Safety of Female PRP Co-incubation With Sperm During (IUI) Cycles","The Efficacy and Safety of Female Autologous Platelet-Rich Plasma (PRP) Co-incubation With Sperm During the Intrauterine Insemination (IUI) Cycles: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients who were eligible for IUI cycles in Assissted Reproduction Technolog unit, Prince of Wales Hospital\n* Female patients aged \\>18 years old and \\\u003C 42 years old\n* BMI \\\u003C 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Concurrent administration of other agents such as prednisolone, intravenous immunoglobulin, or G-CSF\n* Administration of anticoagulants or NSAIDs at least 7 days before PRP infuse\n* Drug addiction\n* Untreated urinary tract infection\n* Underlying uncontrolled diabetes or hypertension, chromosomal or uterine abnormalities, genetic, hematologic, immunological, or endocrine disorders\n* Chronic disease, systemic disease or cancers\n* Blood diseases (sepsis, thrombocytopenia)\n* Poor sperm samples (raw sample TMS \\\u003C5 x 106)\n* Smoking and drinking alcoholic beverages on the day of IUI\n* Fever on the day of IUI\n* Redduse or incomplete in obtaining informed consent","42 Years",{"count":53,"type":22},288,"INTERVENTIONAL",[56],"NA","The investigators hypothesize that infertility patients undergoing IUI who receive female autologous platelet-rich plasma (PRP) co-incubation with husband's sperm would have higher clinical pregnancy rate.\n\nPrimary outcome:\n\nTo compare the incidence of clinical pregnancy outcome in those infertility patients undergoing IUI with female PRP co-incubation with husband's sperm group and non-PRP group.\n\nSecondary outcomes:\n\n* To evaluate the post-culture sperm parameters between the intervention group and control group\n* To evaluate the IUI parameter between the intervention group and control group\n* To evaluate the safeness between the female PRP co-incubation with husband's sperm in the IUI group and non-PRP group, including potential infection rate or other pregnancy outcomes such as miscarriage, multiple pregnancy, ectopic pregnancy and molar pregnancy",[30],"NOT_YET_RECRUITING","2026-05-28",{"date":62,"type":35},"2026-05-29",{"date":64,"type":22},"2026-05-21",{"date":66,"type":22},"2028-05-20",{"name":68,"class":42},"Chinese University of Hong Kong",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":77,"minAge":18,"maxAge":51,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":69},"100622836","impact-of-serum-progesterone-levels-on-embryo-transfer-day-on-clinical-pregnancy-100622836","NCT07388797","Impact of Serum Progesterone Levels on Embryo Transfer Day on Clinical Pregnancy","Impact of Serum Progesterone Levels on Embryo Transfer Day on Clinical Pregnancy in Frozen-thawed Embryo Transfer Cycles Using Hormone Replacement Therapy: a Prospective Observational Study","Inclusion Criteria:\n\n* Patients undergoing FET cycles\n* Infertility patients aged \\>18 years old and \\\u003C 42 years old\n* BMI \\\u003C 30 kg\u002Fm2\n* Transfer of at least one good-quality embryo.\n\nExclusion Criteria:\n\n* Severe endocrine disorders (e.g., thyroid dysfunction, premature ovarian failure).\n* Severe uterine factors without treatment (severe endometriosis, extensive or subendometrial fibroid, uterine adherent, endometrial polyps)","FEMALE",{"count":79,"type":22},370,"Hypotheses:\n\nWe hypothesize that serum progesterone levels on the day of embryo transfer in HRT-FET cycles are positively associated with clinical pregnancy rates.\n\nAims:\n\nTo evaluate the relationship between serum progesterone levels on embryo transfer day and clinical pregnancy outcomes in frozen-thawed embryo transfer cycles using hormone replacement therapy (HRT).\n\nPrimary outcome:\n\nTo compare the incidence of clinical pregnancy outcome in those infertility patients undergoing frozen embryo transfer with caterized Progesterone level on the day of embryo transfer\n\nSecondary outcomes:\n\nBiochemical pregnancy rate. Implantation rate. Early pregnancy loss rate. Ectopic pregnancy rate.",[30],"2026-05-08",{"date":84,"type":35},"2026-05-11",{"date":86,"type":35},"2026-01-20",{"date":88,"type":22},"2028-12-31",{"name":68,"class":42},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":77,"minAge":18,"maxAge":51,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":69},"100619438","factors-associated-with-clinical-pregnancy-outcomes-in-intrauterine-insemination-iui-cycles-100619438","NCT07344623","Factors Associated With Clinical Pregnancy Outcomes in Intrauterine Insemination (IUI) Cycles","Inclusion Criteria:\n\n* Couples who underwent at least one IUI-intrauterine insemination cycle.\n\nExclusion Criteria:\n\n* Couples who used donor sperm.\n* Cases with missing core outcome data",{"count":97,"type":22},3000,"Hypotheses:\n\nWe hypothesize that variations in hormonal profiles (LH, estradiol, progesterone) during ovarian stimulation, follicular response, endometrial characteristics, and sperm quality parameters are significantly associated with clinical pregnancy outcomes in intrauterine insemination (IUI) cycles.\n\nAims\n\n* To investigate the association between hormonal profiles on the trigger day (LH, estradiol, progesterone), follicular response, endometrial thickness, and sperm parameters with clinical pregnancy outcomes in IUI cycles.\n* To develop and validate a predictive model for clinical pregnancy incorporating key determinants such as female age, hormonal response, endometrial characteristics, and sperm quality.\n* To compare natural and gonadotropin-stimulated IUI cycles in terms of hormonal profiles, pregnancy outcomes, and cost-effectiveness.\n\nPrimary Outcome Clinical pregnancy rate (CPR), defined as the presence of a gestational sac with a fetal heartbeat on ultrasound at approximately 6 weeks of gestation following intrauterine insemination.\n\nSecondary Outcomes\n\n* Biochemical pregnancy rate.\n* Ongoing pregnancy rate\n* Live birth rate",[30],{"date":84,"type":35},{"date":102,"type":35},"2026-01-13",{"date":104,"type":22},"2028-01-01",{"name":68,"class":42},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":17,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":69},"100538622","towards-optimal-fertility-fathering-and-fatherhood-study-100538622","NCT06293235","Towards Optimal Fertility, Fathering and Fatherhood studY","Investigating Male Factors and Their Relationships With Reproductive Health Outcomes in Singapore: Towards Optimal Fertility, Fathering and Fatherhood studY","TOFFFY","Inclusion Criteria:\n\nSubfertile couples:\n\n* men aged ≥21-49 years\n* men with a female partner aged 21-39 years\n* couples who are not able to conceive for at least 12 months\n* couples who are Singapore citizen or permanent resident\n\nFertile couples:\n\n* men aged 21-49 years\n* men with a female partner aged 21-39 years\n* men with proven fertility defined as those female partners who are currently pregnant and with viable intrauterine pregnancy at gestational weeks of less or equal to 16 at the time of the study\n* couples with attempted time to conceive within 12 months to achieve this pregnancy or with unplanned pregnancy\n* couples who are Singapore citizen or permanent resident\n\nExclusion Criteria:\n\nSubfertile couples:\n\n* male infertility of a known aetiology including azoospermia, retrograde ejaculation, genetic disorders, cancer treatment, or testes trauma\n* female infertility diagnosis as confirmed by diagnostic imaging or having severe endometriosis\n* female partners with irregular menstrual cycle \\>35 days\n* couples with known chromosomal abnormalities\n\nFertile couples:\n\n* couples who achieve pregnancy after oocyte or spermatozoa donation\n* couples with known chromosomal abnormalities\n* female partners with known uterine abnormalities",true,"21 Years","49 Years",{"count":118,"type":22},960,"This case-control study involving fertile and subfertile couples aims to identify male factors related to pregnancy likelihood, create a fertility index measure combining male and female factors to predict pregnancy likelihood, and examine how male factors relate to the semen physical and biological characteristics.",[30,121],"Fertility Issues",[123,124,125,126,127,128,129],"Male","Risk factor","Lifestyle","Semen analysis","Epigenetic","Oxidative stress","DNA fragmentation","2026-03-17",{"date":132,"type":35},"2026-03-20",{"date":134,"type":35},"2024-06-21",{"date":136,"type":22},"2027-09",{"name":138,"class":139},"KK Women's and Children's Hospital","OTHER_GOV",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":114,"sex":148,"minAge":18,"maxAge":19,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100573142","efficacy-and-safety-of-a-new-sperm-capacitation-method-100573142","NCT06742437","Efficacy and Safety of a New Sperm Capacitation Method","Efficacy and Safety of a New Sperm Capacitation Method: a Prospective in Vitro Study on Semen Samples","HyperSperm01","Inclusion Criteria:\n\n* Ability to provide a semen sample via masturbation\n\nExclusion Criteria:\n\n* Current diagnosis of a sexually transmitted infection (STI)\n* Previous diagnosis of hepatitis A, B, C, D, or HIV\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months","MALE",{"count":150,"type":22},300,"Prospective, multicenter research study with a split-sample design on semen samples, without intervention, to evaluate the efficacy and safety of HyperSperm, a new sperm capacitation method, in 300 semen samples with various characteristics and abnormalities, in an in vitro study over 12 months.",[30,29,153,154,155],"Asthenozoospermia","Oligozoospermia","Teratozoospermia","2026-02-24",{"date":158,"type":35},"2026-02-27",{"date":160,"type":35},"2025-01-14",{"date":162,"type":22},"2026-06",{"name":41,"class":42},4,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":114,"sex":77,"minAge":18,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":54,"phases":174,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":69},"100600056","phase-4-androgen-effects-on-the-reproductive-neuroendocrine-axis-2025-version-100600056","NCT07092527","Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version","Inclusion Criteria: Transgender\u002FNon-binary Group, Initiating Testosterone Group\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Aged 18-35\n* Plan to initiate testosterone therapy\n* History of regular menstrual cycles (every 24-35 days) at baseline, before beginning TRT\n\nInclusion Criteria: Cisgender Female Group\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Aged 18-35\n* Having regular menstrual cycles (every 24-35 days)\n\nExclusion Criteria: All\n\n* Pregnant\n* Incarcerated\n* Known cognitive impairment or institutionalized\n* Hemoglobin less than 11 gm\u002Fdl at screening evaluation\n* Weight less than 110 pounds\n* BMI \\\u003C18 or \\>35\n* Current endocrine disease- including untreated thyroid abnormalities, pituitary or adrenal disease, polycystic ovary syndrome, or androgen producing tumor\n* Current or recent pregnancy within two months of study enrollment\n* Current or recent breast feeding within two months of study enrollment\n* Diabetes, or renal, liver, or heart disease\n* History of oophorectomy or hysterectomy\n* History of radiation or surgery involving brain structures and\u002For pelvis\u002Fpelvic organs\n* Currently taking any medications that may affect their reproductive hormones, such as contraceptive medications, androgens, estrogens, progestins, gonadotropin-releasing hormone (GnRH) antagonists, insulinomimetics, and metformin.\n* History of prior testosterone therapy","35 Years",{"count":173,"type":22},80,[175],"PHASE4","This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.",[178,30],"Transgenderism",{"date":180,"type":35},"2026-01-15",{"date":182,"type":35},"2025-12-05",{"date":184,"type":22},"2028-11-30",{"name":186,"class":42},"University of California, San Diego",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":194,"targetDuration":4,"studyType":54,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":69},"100614648","female-autologous-platelet-rich-plasma-prp-co-incubation-with-husbands-sperm-100614648","NCT07282327","Female Autologous Platelet-Rich Plasma (PRP) Co-incubation With Husband's Sperm","The Efficacy and Safety of Female Autologous Platelet-Rich Plasma (PRP) Co-incubation With Husband's Sperm in the Intrauterine Insemination (IUI) to Improve Clinical Pregnancy Rate: A Prospective, Randomized Controlled Trial.","Inclusion Criteria:\n\n* Patients undergoing IUI cycles\n* Infertility patients aged \\>18 years old and \\\u003C 42 years old\n* BMI \\\u003C30 kg\u002Fm2\n* No sexually transmitted diseases, AIDS, syphilis and other infectious disease\n\nExclusion Criteria:\n\n* Concurrent administration of other agents such as prednisolone, intravenous immunoglobulin, or G-CSF\n* Administration of anticoagulants or NSAIDs at least 7 days before PRP infuse\n* Drug addiction\n* Urinary tract infection\n* Underlying uncontrolled diabetes or hypertension, chromosomal or uterine abnormalities, genetic, hematologic, immunological, or endocrine disorders\n* Chronic disease, systemic disease or cancers\n* Blood diseases (sepsis, thrombocytopenia)\n* Haemoglobin \\\u003C 11g\u002FdL, platelet count \\\u003C 150000 mm3\n* Poor sperm samples (raw sample TMS \\\u003C5 x 106)\n* Smoking and drinking alcoholic beverages on the day of IUI\n* Fever on the day of IUI",{"count":53,"type":22},[56],"Hypotheses:\n\nWe hypothesize that infertility patients undergoing IUI who receive female autologous platelet-rich plasma (PRP) co-incubation with husband's sperm would have higher clinical pregnancy rate.\n\nAims:\n\n* To determine if the use of female autologous platelet-rich plasma (PRP) co-incubation with husband's sperm in the IUI will show higher clinical pregnancy rate (CPR). Clinical pregnancy rate as determined by a positive serum beta-hCG test result and at least one gestational sac at 6 weeks gestation\n* To assess the safety of female PRP co-incubation with husband's sperm in the IUI.\n\nPrimary outcome:\n\nTo compare the incidence of clinical pregnancy outcome in those infertility patients undergoing IUI with female PRP co-incubation with husband's sperm group and non-PRP group.\n\nSecondary outcomes:\n\n* To evaluate the safeness between the female PRP co-incubation with husband's sperm in the IUI group and non-PRP group, including potential infection rate or other complications such as ectopic pregnancy and molar pregnancy\n* To evaluate the sperm quality between the intervention group and control group\n\nData analysis: Data analysis will be performed using Statistical Packages of Social Sciences for Windows\n\nExpected results: The investigators expect that a 50% pregnancy rate increase after the application of female PRP co-incubation with husband's sperm in the IUI",[30],"2025-12-02",{"date":200,"type":35},"2025-12-15",{"date":202,"type":22},"2025-12-10",{"date":204,"type":22},"2027-08-31",{"name":68,"class":42},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":114,"sex":77,"minAge":18,"maxAge":4,"enrollmentInfo":213,"targetDuration":215,"studyType":23,"phases":4,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":69},"100550438","impact-of-a-predetermined-day-5-et-vs-a-predetermined-day-6-et-on-clinical-pregnancy-rate-after-icsi-treatment-100550438","NCT06447077","Impact of a Predetermined Day 5 ET vs. a Predetermined Day 6 ET on Clinical Pregnancy Rate After ICSI Treatment","Impact of a Predetermined Day 5 Embryo Transfer Versus a Predetermined Day 6 Embryo Transfer on the Clinical Pregnancy Rate After Intracytoplasmic Sperm Injection (ICSI) Treatment","Inclusion criteria:\n\nThe patients to be included should be ≥18 years old. There is no upper age limit. Only ICSI treatments with a single embryo transfer (SET) should be included. Only the first cycle per patient should be evaluated.\n\nExclusion criteria:\n\nnone",{"count":214,"type":22},2400,"9 Months","The aim of this prospective multicenter study is to investigate the influence of a predetermined embryo transfer on day 6 compared to a predetermined embryo transfer on day 5. The study population consists of the control group (predetermined embryo transfer on day 5) and the study group (predetermined embryo transfer on day 6). The primary endpoint is the clinical pregnancy rate (detection of a gestational sac) per embryo transfer and the secondary endpoint is the abortion rate per clinical pregnancy. The data from the multicenter study are obtained at three test centers (Fertility Center Dortmund, Fertility Center Essen and Fertility Center Bad Münder).",[218,30],"Infertility",[27,220,221],"Predetermined Day 6 Embryo Transfer","Predetermined Day 5 Embryo Transfer","2025-07-21",{"date":224,"type":35},"2025-07-24",{"date":226,"type":35},"2024-06-26",{"date":228,"type":22},"2028-03",{"name":230,"class":42},"Infertility Treatment Center Dortmund",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":54,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":69},"100508153","a-novel-integrative-non-invasive-embryo-selection-approach-for-ivf-based-on-mk-rs-analysis-100508153","NCT05896709","A Novel Integrative Non-invasive Embryo Selection Approach for IVF Based on MK-RS Analysis","A Novel Integrative Non-invasive Embryo Selection Approach for in Vitro Fertilization Based on Artificial Intelligence Enhanced Morphokinetic Analysis and Raman Spectra in Spent Culture Media","Inclusion Criteria:\n\n1. Patients undergoing IVF\u002F ICSI treatment\n2. Patients receiving the first, second or third IVF\u002FICSI treatment cycle\n3. Patients and their partners willing to sign the informed consent agreement\n4. Patients having at least three normal fertilised embryos on the day of the fertilization check\n5. Consecutive women undergoing IVF treatment\n6. Patients planning to use a time-lapse incubator for embryo culture\n\nExclusion Criteria:\n\n1. Day one human embryos with blur imaging\n2. Large obstructions in the embryo area\n3. More than half of the embryo area is blocked by the well or degeneration\n4. Patients with more than half of the embryos without sufficient spent culture medium for RS analysis\n5. Patients with known genetic diseases",{"count":239,"type":22},176,[56],"During assisted reproductive technology treatment, embryo selection is an important process that may affect the clinical pregnancy rate. Many assisted reproductive technology units over the world have tried different approaches to increase the clinical pregnancy rate. Conventionally, the morphology of the embryo is assessed by the embryologist with naked eyes only. Nowadays, artificial intelligence (AI) has been used to assist in morphological assessment of the embryo. Our pilot study showed that the AI-enhanced morphokinetic (MK) analysis increased the accuracy in embryo selection by \\~9%, while the detection rate for abnormal chromosomes in embryo has also been increased by Raman spectroscopy (RS) analysis. The combined MK-RS analysis will be able to complete embryo assessment within 5-6 days after fertilization. This method needs shorter time and is at lower cost when compared to invasive preimplantation genetic testing for aneuploidies (PGT-A).\n\nIn this study, we have combined the following non-invasive techniques to assist in embryo screening.\n\n1. Using time-lapse imaging (i.e. images of embryo being taken every 10 minutes inside the incubator) with AI)-enhanced MK analysis to assess the entire morphological changes of the embryo.\n2. As the embryo releases metabolites during its growth, the spent culture medium will be collected after culture of the embryo and then be used for RS analysis, which is a kind of metabolomics-based non-invasive PGT-A, for screening chromosomal abnormalities of the embryo.\n\nThis study will include two phases. In Phase I, it is a retrospective part. We will collect data to train the convolutional neural network (CNN)-enhanced MK with RS method on embryo selection, leading to the integrated approach (MK-RS). In Phase II, it is a randomized controlled trial and participants will be randomised into 2 groups. For the experimental group, embryo selection will be based on the MK-RS method, whereas embryo selection for the control group will rely on the traditional embryo assessment results alone. Then we will assess the clinical pregnancy rate and evaluate the efficacy of our approach finally. Patients who receive in vitro fertilisation (IVF)\u002F intracytoplasmic sperm injection (ICSI) treatment from The Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong, Prince of Wales Hospital will be recruited.",[30,243,244],"Subfertility","IVF",[246,247,248,249,250,251,252],"non-invasive","in vitro fertilization","time-lapse imaging","artificial intelligence","morphokinetic analysis","Raman spectroscopy","embryo selection","2025-03-18",{"date":255,"type":35},"2025-03-21",{"date":257,"type":35},"2023-07-17",{"date":259,"type":22},"2026-12",{"name":68,"class":42}]